Arterya ouvre son capital au grand public pour faciliter le prélèvement artériel
法国医疗科技初创公司Arterya近日向公众开放股权融资，旨在推广其革命性的动脉采血技术。该公司开发了一种便携式设备，可简化动脉血液样本采集流程，传统方法通常需要专业医护人员操作且患者不适感较强。
此次公开募股通过股权众筹平台进行，最低投资额仅为100欧元，使普通公众也能参与医疗技术创新。公司计划利用所筹资金加速产品临床试验，并推进欧洲医疗器械认证。
Arterya的核心技术采用微型传感器和智能压力控制系统，能自动定位桡动脉并安全完成采血。该设备已获得法国国家创新署资助，并与多家医院建立临床合作。创始人强调，这项创新有望减轻医护人员工作负担，并提升慢性病患者居家监测的可行性。
市场分析指出，全球动脉血气分析市场规模预计2025年将达50亿美元，而当前采血技术仍是行业痛点。若Arterya成功获得CE认证，其设备可能率先在欧洲糖尿病和呼吸疾病管理领域实现商业化应用。
Arterya Opens Equity to Public Investment to Advance Arterial Blood Sampling Device
French medtech startup Arterya has launched a public equity fundraising campaign, inviting retail investors to participate in its €1.5 million financing round. This move aims to support the final development and market entry of its flagship product: a novel medical device designed to simplify and improve arterial blood sampling.
Arterial blood gas analysis is a critical procedure for monitoring patients with severe respiratory or metabolic conditions. However, the current method—performed manually by a clinician—is technically challenging, painful for patients, and carries risks of complications like hematomas or nerve damage. Arterya’s solution is a compact, single-use, and connected device intended to make the procedure safer, less painful, and accessible to a broader range of healthcare professionals, not just specialized doctors.
The company, founded in 2021 and based in Nantes, has already secured €2.3 million in previous funding rounds from business angels and regional grants. The current €1.5 million campaign, conducted via the crowdfunding platform Sowefund, is structured with a minimum investment threshold of €100. The funds are earmarked for obtaining CE marking (the European regulatory approval), initiating industrial production, and preparing for commercial launch in Europe.
Arterya’s leadership highlights the significant market need. "Thousands of arterial punctures are performed daily in hospitals, but the procedure remains difficult and under-performed due to its complexity," notes the company. The device aims to address this by integrating several functions into one sterile instrument, potentially improving patient comfort and clinical efficiency.
If successful, the capital raise will position Arterya to enter a substantial market, with the global arterial blood sampling sector valued at approximately $3 billion. The public investment window is open until July 18, 2024.
L’article Arterya ouvre son capital au grand public pour faciliter le prélèvement artériel est apparu en premier sur Maddyness - Le média pour comprendre l'économie de demain.